⭐️⭐️⭐️ The 10000th participant ⭐️⭐️⭐️was recruited to the Lymphoma and Related Diseases Registry! Congratulations and thanks to all participants, participating sites and staff, principal investigators and supporters.

An important review exploring how the gut microbiome may act as an immune gate-keeper in B-cell lymphoma has been published in Blood Reviews. The review was authored by our team specialising in lymphoma and collaborators at QIMR Berghofer ➡️ https://ow.ly/coGe50XKHwl #BCellLymphoma Prof Eliza Hawkes

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

PURPOSEAlthough most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression ...

ascopubs.org

During our latest steering committee meeting, Gareth Gregory chaired a discussion on Glofit-GemOx in patients with R/R DLBCL. Learn more: https://loom.ly/YpxZNZM #lymphoma #lymsm #MedEd #MedNews

We are excited to launch our new initiative - Women in Lymphoma Academy CAR-T Educational Internship. Applications are invited for a 2 week internship commencing August 2026 in Singapore. Eligibility criteria and application information can be found at womeninlymphoma.org/wil-academy

Dr Zoe Loh kicked off her PhD with this review of newer MCL biomarkers in the era of targeted therapies. Great expert input also from Dr Paul yeh and A/Prof Colm Keane. @onjcri.org.au haematologica.org/haematologic...

Our fantastic @onjcri.org.au and @lardr.bsky.social teams presenting lymphoma research orals at #HSANZ Blood conference in Perth. Dr Liz Goodall, Dr Allison barraclough, Eliza Chung and Rebecca nightingale and Dr Arina Martynchyk. All rising @womeninlymphoma.bsky.social

Our next webinar series on MCL starts on Oct 29th with Dr Maria Gomes da Silva, Dr Christine Ryan, Dr Clémentine Sarkozy and Dr Ann LaCasce Register ➡️ us06web.zoom.us/webinar/regi...

WiLing Wednesday's Webinars are back! Join us for updates on various MCL topics presented by global experts, starting Oct 29 through to Nov 19. Register on our website : womeninlymphoma.org/webinars First session on Oct 29 : us06web.zoom.us/webinar/regi...

Thanks to Dr Yamshon and @johnpleonardmd.bsky.social for your excellent editorial: Unstacking the deck in follicular lymphoma clinical trials url: academic.oup.com/jnci/article... In response to our paper here: academic.oup.com/jnci/article...

Unstacking the deck in follicular lymphoma clinical trials

Treating follicular lymphoma is a marathon, not a sprint. From the moment of diagnosis, patients must carefully balance short-term efficacy and toxicity wi

academic.oup.com

T‐Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B‐Cell Lymphoma - Wight - 2025 - eJHaem - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...

T‐Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B‐Cell Lymphoma

Background Tumour infiltrating lymphocyte (TIL) T-cell receptor (TCR) repertoire is prognostic in newly diagnosed diffuse large B-cell lymphoma (DLBCL), but evolution has not been evaluated at relap.....

onlinelibrary.wiley.com

Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival url: academic.oup.com/jnci/article...

Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival

AbstractBackground. Clinical trial eligibility criteria are necessary for safety and target population homogeneity; however, increasingly restrictive organ

academic.oup.com

Please join us on 1 August for the inaugural open meeting of the OPTIMAL CRE in improving immunoglobulin use! www.optimalcre.org We'll have updates on research projects underway, and lots of opportunities to join the discussion. Registration details below. Everyone is welcome, in person or online!

OPTIMAL CRE@optimal-cre.bsky.social · last yr.

Registration for the OPTIMAL CRE Inaugural Open Meeting in Melbourne is now open! Join patients, clinicians and researchers on 1 August as we explore key challenges and innovative approaches to improving immunoglobulin use. 👉 Register in person or online now: OPTIMALCRE2025.eventbrite.com.au

Our multidisciplinary study of RT + immunotherapy with CD8 PET as a biomarker of response in relapse B-NHL ashpublications.org/bloodadvance...

T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trial.

Key Points. Delivering radiotherapy to multiple disease sites in combination with immunotherapies such as PDL1 inhibitors is safe.T-cell dysregulation iden

ashpublications.org

Thanks to all who stopped by to chat with us at our #FollicularLymphoma #EHA2025 poster 👋 @hemasphere-journal.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social #LymphomaResearch #ClinicalResearch #Registry

LaRDR at EHA conference 2025!

lardr.org

We're also showcasing our #18ICML posters: -221, real-world data on end-of-treatment imaging #TCellLymphoma; -390, Ki67 expression level in #FollicularLymphoma See you June 18👋 @icmlugano.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social #LymphomaResearch #ClinicalResearch #Registry

END‐OF‐TREATMENT PET/CT COMPLETE REMISSION IS HIGHLY PROGNOSTIC IN NODAL PERIPHERAL T‐CELL LYMPHOMA: AN AUSTRALASIAN‐CANADIAN COLLABORATIVE STUDY

Click on the article title to read more.

doi.org

Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL. • operationally deliverable with ctDNA turnaround median 9d • low rate PET+ and ctDNA+ at interim • assessing whether acala addition benefits those with Myd88 &/or CD79b mutns SAKK38/19 trial #ICML18

PROs from BRUIN-321 pirto vs idelaR/BR R/R CLL #18ICML - pirto: better improvements in CLL-related sx, physical function, fatigue, all clinically significant - 83% PRO completion pirto at week 25, only 59% other arm Grain of salt given PRO dropout, but well reported. #lymsm

We're excited to meet you at our #EHA2025 poster PS1885 to talk about the study of Ki67 expression in Australasian #FollicularLymphoma patients. See you Saturday, June 14 👋 @hemasphere-journal.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social #LymphomaResearch #ClinicalResearch #Registry

Join us now at our poster in #ASCO2025 to discuss gender demographics and equity in professional opportunities!

Pleased to work with my U.K. colleagues this analysis of PET data from our CHEMO-T study in PTCL led by #drgleeson and #drchua onlinelibrary.wiley.com/doi/10.1111/...

The role of PET/CT in peripheral T‐cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO‐T trial

A PET/CT substudy of the UK NCRI CHEMO-T phase 2 trial was performed to further investigate the role of PET/CT in previously untreated patients with peripheral T-cell lymphoma (N = 82). Our findings ...

onlinelibrary.wiley.com

The Lymphoma and Related Diseases Registry enrolled the ⭐9000th⭐ participant on May 8, 2025! We would like to express our sincere gratitude to all participants, participating sites and staff, principal investigators and industry partners for their continued support of the registry 🙌

Our study showing 3D volume assessment of PCNSL on MRI is more accurate than standard criteria in response assessment and prognostication. academic.oup.com/noa/advance-...

Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-Dimensional MRI

AbstractBackground. Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma restricted to the CNS in which outcomes cannot be reliably pr

academic.oup.com

Join us tomorrow for last webinar of this series "Careers in Pharma" with Dr Connie Batlevi & Jamie Hirata along with Casulo Carla & Judith Trotman Register at us06web.zoom.us/webinar/regi...

📢 We are excited to announce that the #18ICML Scientific Programme IS ONLINE: shorturl.at/FlsmC Thank you to our international Advisory Board and reviewers for their precious help!

Don't miss the last webinar of this series next week with Connie Batlevi & Jamie Hirata presenting on Careers in Pharma along with Casulo Carla & @judithtrotman.bsky.social ! Register at us06web.zoom.us/webinar/regi...

Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma buff.ly/2sCOERm #hemesky #bloodspotlight #lymphoidneoplasia

LaRDR supports early-career clinician-researchers by providing #research opportunities📊. They gain experience in manuscript writing ✍️ for publication and conference presentations. Tune in to this interview to hear more from Dr Wang! 🎬 youtu.be/0rjytiYHhuY

LaRDR Interview - Research experience from basic physician to haematology registrar

YouTube video by Transfusion Research Unit

youtu.be

Join Dr Julia Brain & Dr Candice McCoy tomorrow @ 4pm EST for the 3rd webinar of this series "Successful Research Collaboration", hosted by our Steering Committee members Dr Carla Casulo , Dr Wendy Osborne & Dr Ann LaCasce Register @ us06web.zoom.us/webinar/regi...

Spreading the word about MyHodgkin MyHealth: Our interview with @normanswan on ABC Radio’s Health Report. MHMH is open now in Australia for any HL survivors to join abc.net.au/listen/program… @janfalconer